Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Henrotin, Yves ^a,b   Gharbi, Myriam ^a   Dierckxsens, Yvan ^c   Priem, Fabian ^d   Marty, Marc ^e   Seidel, Laurence ^a   Albert, Adelin ^a   Heuse, Elisabeth ^f   Bonnet, Valérie ^f   Castermans, Caroline ^f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Princess Paola Hospital   (Belgium)

^c Tilman SA ZI Sud   (Belgium)

^d Bioxtract S A Parc Scientifique Créalys   (Belgium)

^e HENRI MONDOR HOSPITAL   (France)

^f Department of Rheumatology Hôpital Henri Mondor ^*  (Belgium)

Author keywords

Biomarker; Cartilage; Collagen; Curcumin; Osteoarthritis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 2; CURCUMIN; FIBULIN; FIBULIN 3; FLEXOFYTOL; MYELOPEROXIDASE; POLYSORBATE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; EFEMP1 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PEROXIDASE; SCLEROPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; FEMALE; GLOBAL ASSESSMENT OF DISEASE ACTIVITY; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; LIMIT OF DETECTION; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PROTEIN BLOOD LEVEL; VISUAL ANALOG SCALE; BLOOD; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; OSTEOARTHRITIS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PHYTOTHERAPY; TREATMENT OUTCOME; URINE;

AGED; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLLAGEN; COLLAGEN TYPE I; CURCUMIN; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PEPTIDES; PEROXIDASE; PHYTOTHERAPY; TREATMENT OUTCOME;

EID: 84901508680     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-159     Document Type: Article

References (42)

1. Samuels J, Krasnokutsky S, Abramson SB. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66:244-250.
2. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681. 10.1136/ard.2004.028886, 1755499, 15471891.
3. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162. 10.1016/j.joca.2007.12.013, 18279766.
4. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000. 10.1016/j.joca.2007.06.014, 17719803.
5. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499. 10.1016/j.joca.2010.01.013, 20170770.
6. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155. 10.1136/ard.2003.011742, 1754382, 14644851.
7. Ameye LG, Chee WS. Osteoarthritis and nutrition: from nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 2006, 8:R127. 10.1186/ar2016, 1779427, 16859534.
8. Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthritis Cartilage 2011, 19:1-21. 10.1016/j.joca.2010.10.017, 21035558.
9. Kalra EK. Nutraceutical-definition and introduction. AAPS PharmSci 2003, 5:E25. 2750935, 14621960.
10. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage 2010, 18:141-149. 10.1016/j.joca.2009.10.002, 19836480.
11. Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products?. Trends Mol Med 2012, 18:138-144. 10.1016/j.molmed.2012.01.004, 22386732.
12. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010, 62:919-930. 10.1080/01635581.2010.509835, 20924967.
13. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it?. Mol Nutr Food Res 2008, 52:1010-1030. 10.1002/mnfr.200700354, 18384098.
14. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as " Curecumin" : from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809. 10.1016/j.bcp.2007.08.016, 17900536.
15. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010, 30:173-199. 10.1146/annurev.nutr.012809.104755, 3144156, 20420526.
16. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59. 10.1016/j.biocel.2008.06.010, 2637808, 18662800.
17. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30:85-94. 10.1016/j.tips.2008.11.002, 19110321.
18. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011, 16:4567-4598. 10.3390/molecules16064567, 21642934.
19. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springerplus 2013, 2:56. 10.1186/2193-1801-2-56, 3591524, 23487030.
20. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012, 26(11):1719-1725. 10.1002/ptr.4639, 22407780.
21. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010, 15:337-344.
22. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegard D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011, 19:515-542. 10.1016/j.joca.2010.08.019, 3568396, 21396468.
23. Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: what do they indicate?. Curr Opin Rheumatol 2007, 19:444-450. 10.1097/BOR.0b013e32829fb3b5, 17762609.
24. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee: diagnostic and therapeutic criteria committee of the american rheumatism association. Arthritis Rheum 1986, 29:1039-1049. 10.1002/art.1780290816, 3741515.
25. Henrotin Y, Deberg M, Dubuc JE, Quettier E, Christgau S, Reginster JY. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004, 41:543-547.
26. Henrotin Y, Gharbi M, Mazzucchelli G, Dubuc JE, De Pauw E, Deberg M. Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum 2012, 64:2260-2267. 10.1002/art.34392, 22275171.
27. Christgau S, Henrotin Y, Tanko LB, Rovati LC, Collette J, Bruyere O, Deroisy R, Reginster JY. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004, 22:36-42.
28. Clutterbuck AL, Allaway D, Harris P, Mobasheri A. Curcumin reduces prostaglandin E2, matrix metalloproteinase-3 and proteoglycan release in the secretome of interleukin 1beta-treated articular cartilage. F1000Res 2013, 2:147. 3901452,3901452, 24555068.
29. Buhrmann C, Mobasheri A, Matis U, Shakibaei M. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther 2010, 12:R127. 10.1186/ar3065, 2945017, 20594343.
30. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 2013, 169:1672-1692. 10.1111/bph.12131, 23425071.
31. Ameye LG, Deberg M, Oliveira M, Labasse A, Aeschlimann JM, Henrotin Y. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum 2007, 56:3336-3346. 10.1002/art.22875, 17907187.
32. Henrotin Y, Martel-Pelletier J, Msika P, Guillou GB, Deberg M. Usefulness of specific OA biomarkers, Coll2-1 and Coll2-1NO2, in the anterior cruciate ligament OA canine model. Osteoarthritis Cartilage 2012, 20:787-790. 10.1016/j.joca.2012.03.016, 22469849.
33. Huebner JL, Williams JM, Deberg M, Henrotin Y, Kraus VB. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage 2010, 18:397-405. 10.1016/j.joca.2009.09.011, 2826602, 19825496.
34. Verwilghen DR, Martens A, Busschers E, Franck T, Deberg M, Henrotin Y, Vanderheyden L, Serteyn D. Coll2-1, Coll2-1NO2 and myeloperoxidase concentrations in the synovial fluid of equine tarsocrural joints affected with osteochondrosis. Vet Res Commun 2011, 35:401-408. 10.1007/s11259-011-9487-5, 21681550.
35. Deberg M, Dubuc JE, Labasse A, Sanchez C, Quettier E, Bosseloir A, Crielaard JM, Henrotin Y. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 2008, 67:168-174. 10.1136/ard.2007.073452, 17644542.
36. Deberg M, Labasse A, Christgau S, Cloos P, Bang Henriksen D, Chapelle JP, Zegels B, Reginster JY, Henrotin Y. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13:258-265. 10.1016/j.joca.2004.12.002, 15727893.
37. Henrotin Y, Chevalier X, Deberg M, Balblanc JC, Richette P, Mulleman D, Maillet B, Rannou F, Piroth C, Mathieu P, Rannou F, Conrozier T. Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study. J Orthop Res 2013, 31:901-907. 10.1002/jor.22297, 23423846.
38. Henrotin Y, Labasse A, Franck T, Bosseloir A, Bury T, Deberg M. Collagen catabolism through Coll2-1 and Coll2-1NO and myeloperoxidase activity in marathon runners. Springerplus 2013, 2:92. 10.1186/2193-1801-2-92, 3601271, 23519606.
39. Punzi L, Ramonda R, Deberg M, Frallonardo P, Campana C, Musacchio E, Henrotin Y. Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands. Osteoarthritis Cartilage 2012, 20:557-561. 10.1016/j.joca.2012.02.638, 22401873.
40. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445. 10.1016/j.bcp.2007.01.005, 17291458.
41. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005, 13:361-367. 10.1016/j.joca.2005.01.005, 15882559.
42. Roemer FW, Guermazi A, Felson DT, Niu J, Nevitt MC, Crema MD, Lynch JA, Lewis CE, Torner J, Zhang Y. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheum Dis 2011, 70:1804-1809. 10.1136/ard.2011.150243, 3496084, 21791448.